A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples